復宏漢霖-B(02696.HK)創新藥獲藥監局批準治療實體瘤患者
復宏漢霖-B(02696.HK)公佈,國家藥監局(NMPA)近日已附條件批準公司自主開發的創新抗PD-1單抗漢斯狀(斯魯利單抗注射液)用於治療不可切除或轉移性微衛星高度不穩定(Microsatellite InstabilityHigh, MSI-H)(MSI-H)的成人晚期實體瘤患者。
當中包括治療既往經過氟尿嘧啶類、奧沙利鉑和伊立替康治療後出現疾病進展的晚期結直腸癌患者;既往至少二線治療後出現疾病進展且無滿意替代治療方案的晚期胃癌患者;既往至少一線治療後出現疾病進展且無滿意替代治療方案的其他晚期實體瘤患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.